The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Geneos; Ipsen; Lilly O.; Merck; Roche; Universal Diagnostics
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Gilead Sciences; Lilly O.; Roche
Research Funding - Bayer (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; TERUMO
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Maria Reig
No Relationships to Disclose
 
Silvia Damian
Employment - Biofarma Group (I)
Leadership - Biofarma Group (I)
Research Funding - Basilea Pharmaceutical (Inst); Incyte (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Domenico Roberti
Employment - Nerviano Medical Sciences
Consulting or Advisory Role - Agios; Nerviano Medical Sciences
 
Sara Maruzzelli
Employment - Nerviano Medical Sciences
 
Fabio Gasparri
Employment - Nerviano Medical Sciences
Patents, Royalties, Other Intellectual Property - Nerviano Medical Sciences
 
Pamela Ghioni
Employment - Nerviano Medical Sciences
 
Maria Teresa De Pietro
Employment - Nerviano Medical Sciences
 
Tiziana Pressiani
Consulting or Advisory Role - AstraZeneca; Bayer; Ipsen
Research Funding - AstraZeneca; Bayer; Roche
Travel, Accommodations, Expenses - Roche
 
Marco Sanduzzi Zamparelli
Honoraria - Bayer
Speakers' Bureau - Bayer; BTG; Eisai; Roche
 
Matteo Duca
No Relationships to Disclose
 
Alessia Montagnoli
Employment - Nerviano Medical Sciences
 
Arturo Galvani
Employment - Nerviano Medical Sciences
 
Elena Ardini
Employment - Nerviano Medical Sciences
 
Antonella Isacchi
Employment - Nerviano Medical Sciences
 
Cristina Davite
Employment - Nerviano Medical Sciences
 
Patrizia Crivori
Employment - Nerviano Medical Sciences
 
Lisa Mahnke
Employment - Nerviano Medical Sciences; SERVIER
Leadership - Nerviano Medical Sciences
Stock and Other Ownership Interests - Vertex
Travel, Accommodations, Expenses - Nerviano Medical Sciences; SERVIER